Craig Snyder, CEO of Indigo Global Corporation and Political and Corporate consultant, suggests the Biden Administration initiate a massive vaccine diplomacy initiative and purchase various vaccines including COVAXIN, to vaccinate majority of humanity across the globe to control the pandemic.
Data showing Covaxin-induced sera can neutralize B.1.617 as well as the B.1.128 variant first identified in Brazil has the stock up 24% to $15.68 for a valuation of $3.1 billion.
Since Tuesday's market close, the Malvern biopharmaceutical company's stock has surged 128% from $5.52 per share to $12.57.
JP Gabriel watched from the bleachers as the pandemic raged. Now head of manufacturing at Ocugen, he’s ready to bat
Gabriel has joined Ocugen as SVP of manufacturing and supply as the company looks to bring Covaxin to market.
Sanjay Subramanian provides a development update on the pre-EUA COVID-19 vaccine and R&D ophthalmology pipeline.
Ocugen and Bharat Biotech plan to seek emergency use authorization later this month from the U.S. Food and Drug Administration.
Kristen Kluska of Cantor Fitzgerald hosted a virtual fireside chat featuring CEO Dr. Shankar Musunuri and members of the Vaccine Scientific Advisory Board to discuss COVAXIN vaccine development in the US.
Eye-health company Ocugen shares surge more than 425 percent year-to-date after the company got involved in distributing Covid-19 vaccines. Shankar Musunuri, Ocugen CEO, joins ‘Closing Bell’ to discuss.
Through a partnership between leading vaccine developer Bharat Biotech and Pennsylvania-based biopharmaceutical company Ocugen, India is seeking to extend vaccine diplomacy to the United States’ effort to immunize its population against Covid-19.
Ocugen Inc. is tackling retinitis pigmentosa (RP), which is caused by mutations in well over 100 mutations.
Chester County biopharmaceutical company Ocugen has finalized an agreement with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine for the United States market.
While Ocugen has focused on developing gene therapy treatments for retinal diseases since its inception in 2013, the Malvern biopharmaceutical company expanded into a new arena two weeks ago. On Dec. 22, Ocugen announced it signed a binding letter of intent with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine candidate for the United States market.
The Indian company Bharat Biotech partnered with the National Institute of Virology and the Indian Council of Medical Research to develop an inactivated coronavirus vaccine called Covaxin.
India’s drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot. COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research (ICMR).
CEOs of biopharma organizations face unprecedented challenges as they lead their companies amid a global pandemic, shoring up their organizations during turmoil, and learning valuable lessons along the way.